BedikianA.Y., BodeyG.P., ValdiviesoM., BurgessM.A.: Phase I evaluation of oral tegafur, Cancer Treat.Rep., 67: 81–84, 1983.
2.
CaoS., DurraniF., MaueR., RustumY.M.: Modulation of the antitumor activity of ftorafur (FT) and uracil (U)-Ft combination (UFt) in rats bearing advanced colon carcinoma, Proc.Am. Soc. Clin. Oncol.,12: 212, 1993.
3.
CaoS., FrankC., ShirasakaT., RustumY.: 5-fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.Clinical Cancer Research., 1: 839–845, 1995.
4.
CaoS., RustumY.M., SpectorT.: 5-ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.Cancer Research., 54: 1507–1510, 1994.
5.
DanhauserL.L., RustumY.M.: A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combinations.J. Lab. & Clin. Med., 93: 1047–1053, 1979.
6.
FriedmanM.A., IgnoffoR.J.: A review of the United States clinical experience of the fluoropyrimidine ftorafur (NS-C148958.Cancer Treat. Rev., 7: 205–213, 1980.
7.
FukuiY., ImabayashiN., NishiiM.: Clinical study on the enhancement of drug delivery into tumor tissue by UFT.Jpn. J. Cancer Chemother., 7: 2124–2129, 1980.
8.
FujiiS., KitanoS., IkenakaK., ShirasakaT.: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents.Gann., 70: 209–214, 1978.
9.
FujiiS., KitanoS., IkenakaK., ShirasakaT.: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of l-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents., Gann., 70: 209–214, 1979.
HoD.H., PrazdurR., CovingtonW., BrownN., LassereY., LinS., RustumY., CreavenP., NewmanR.A., KrakoffI., Kuritani: Correlation of pharmacokinetics of FU with toxicity of patients treated orally with uracil and ftorafur (4: 1 molar ratio) + leucovorin.Proc. Am. Assoc. Cancer Res.,35: 241, 1994.
12.
JaiyesimiI., PazdurR., HoD.H., LassereY., MooreD.Jr., BreadyB., KrakoffI.H.: Phase I trial of UFT (ftorafur plus uracil) and leucovorin: 28 day schedule.Proc. Am. Soc. Clin. Oncol.,12: 152, 1993.
13.
JaiyesimiI., PazdurR., RhodesV., LassereY., SooE., BreadyB.: Phase I study of tegafur plus uracil co-administered with oral leucovorin.Proc. Am. Soc. Clin. Oncol.,13: 164, 1994.
14.
KimuraK., SugaS., ShimajiT., KitamuraM., SuzuokiY., IsobeK.: Clinical basis of chemotherapy for gastric cancer with uracil and 1(2'-tetrahydrofuryl)-5-fluorouracil.Gastroenterol. Jpn., 15: 324–329, 1980.
15.
Kohne-WompnerC.H., SchmollH.J., HarstrickA., RustumY.M.: Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.Semin. Oncol., 19: 105–125, 1992.
MaeharaY., KusumotoT., KusumotoH., AnaiH., SugimachiK.: UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, (1-2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil.Chemotherapy, 34: 484–489, 1988.
18.
MaecharaY., KusumotoT., KusumotoH., AnaiH., SakaguchiY., KiddoY., OkamuraT., KorenagaD., SugimachiK.: 5-fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase.Cancer, 63: 1693–1696, 1989.
19.
MalikS.T.A., TalbotD., ClarkeP.I., OsborneR., ReznekR., WrigleyP.F.M., SlevinM.L.: Phase II trial of UFT in advanced colorectal and gastric cancer.Br. J. Cancer, 62: 1023–1025, 1990.
20.
MeropolN.J., CreavenP.J., PetrelliN.J., Rodiguez-BioasM., FrankC., HoD.H., RustumY.M.: A phase I and pharmacokinetics study of oral UFT and leucovorin (LV).Proc. Am. Soc. Clin. Oncol.,13: 160, 1994.
21.
OtaK., TaguchiT., KimuraK.: Report on nationwide pooled data and cohort investigation in UFT phase II study.Cancer Chemother. Pharmacol., 22: 333–338, 1988.
22.
PazdurR., LassereY., RhodesV., AjaniJ.A., SugarmanS.M., PattY.Z., JonesD.V.Jr., MarkowitzA.B., AbbruzzeseJ.L., BreadyB., LevinB.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.J. Clin. Oncol., 12: 2296–2300, 1994.
23.
PiedboisP., BuyseM., RustumY., MachoverD., ErlichmanC., CarlsonR.W., ValoneF., LabiancaR., DoroshowJ.H., PetrelliN.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate.J. Clin. Oncol., 10: 896–903, 1992.
24.
PorterD.J.T., ChestnutW.G., MerrillB.M., SpectorT.: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil.J. Biol. Chem., 267: 5236–5242, 1992.
25.
RustumY.M.: Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin.Cancer, 63: 1013–1017, 1989.
26.
RustumY.M., CaoS., SpectorT.: 5-ethynyluracil (776C85) is a potent modulator of the therapeutic activity of 5-fluorouracil.Proc. Am. Assoc. Cancer Res.,34: 283, 1993.
27.
ShirasakaT., NakanoK., TakechiT., SatakeH., UchidaJ., FujiokaA., SaitoH., OkabeH., OyamaK., TakedaS., UnemiN., FukushimaM.: Antitumor activity of 1M tegafur-0.4 M 5-chloro-2-4-dihydroxypyrimidine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.Cancer Res., 56: 2602–2606, 1996.
28.
SpectorT.: 5-ethynyluracil (776C85): an inactivator of uracil reductase that potentiates the antitumor activity of 5-fluorouracil.Curr. Opin. Ther. Patients, 3: 1751–1754, 1993.
29.
SpectorT., HarringtonJ.A., PorterD.J.T.: 5-ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.Biochem. Pharmacol., 46: 2243–2248, 1993.
30.
TaguchiT., NakanoY., FujiS., ShirasakaT.: Determination of 5-fluorouracil levels in tumors, blood and other tissues.Cancer Chemother., 5: 1167–1172, 1978.
31.
TaguchiT., NakanoY., JikuyaK., FujiiS., IkenakaK., FukushimaM., ShirasakaT.: Effect of uracil on the antitumor activity of ftoraful.Gan To Kagaku Ryoho, 5: 1161–1163, 1978.
32.
ToideH., AklyoshiH., MinatoY., OkudaH., FujiiS.: Comparative studies on metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.Gann., 68: 553–560, 1977.
33.
UnemiN., TakedaS., TajimaK., KawaguchiY., YasudaA.: Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil.Chemotherapy, 29: 164–175, 1981.
34.
ZhangZ.G., HarstrickA., RustumY.M.: Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.Semin. Oncol., 19: 10–15, 1992.
